Abstract
Hypercholesterolemia constitutes one of the main cardiovascular risk factors and, consequently, treat it is really important to limit the risk of one of the leading causes of death in developed countries.
Therefore, an effective treatment to reduce high cholesterol is necessary: statins have proved to be the gold standard among lipid-lowering drugs, but at the cost of many unpleasant side effects.
At the same time, many nutraceuticals or functional foods were identified to lower levels of LDL cholesterol, acting according to different mechanisms of action.
Soluble fiber, glucomannan, plant sterols and probiotics inhibit the absorption of cholesterol and biliary salts by the bowel; monacolins, polycosanols, garlic and bergamot inhibit HMG-CoA reductase, limiting the hepatic synthesis of cholesterol; berberine, soy proteins and green tea act as inducers of LDL cholesterol excretion.
Clinical trials have shown that these nutraceuticals have an additive effect to statins, allowing to reduce the doses of statins without decreasing the results in terms of effectiveness in reducing total and LDL-cholesterol and significantly limiting side effects.
The results of the studies carried out have been encouraging, but further clinical trials prolonged over time are required to better assess the potential and possible long-term side effects of nutraceuticals and their combination with statins.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ackermann RT, et al. Garlic shows promise for improving some cardiovascular risk factors. Arch Intern Med. 2001;161:813–24.
Affuso F, et al. A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome. World J Cardiol. 2012;4:77–83.
Anderson GD, et al. Drug interaction potential of soy extract and Panax ginseng. J Clin Pharmacol. 2003;43:643–8.
Anderson JW, et al. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med. 1995;333:276–82.
Berginc K, et al. Garlic flavonoids and organosulfur compounds: impact on the hepatic pharmacokinetics of saquinavir and darunavir. Drug Metab Pharmacokinet. 2010;25(6):521–30.
Berthold HK, et al. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized, controlled trial. JAMA. 2006;295:2262–9.
Brashears MM, et al. Bile salt deconjugation and cholesterol removal from media by Lactobacillus casei. J Dairy Sci. 1998;81:2103–10.
Burcelin R, et al. The gut microbiota ecology: new opportunity for the treatment of metabolic diseases? Front Biosci. 2009;14:5107–17.
Cambria-Kiely JA. Effect of soy milk on warfarin. Ann Pharmacother. 2002;36:1893–6.
Cani PD, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009;58(8):1091–103.
Chan E. Displacement of bilirubin from albumin by berberine. Biol Neonat. 1993;63:201–8.
Chen ST, et al. Variable effects of soy protein on plasma lipids in hyperlipidemic and normolipidemic hemodialysis patients. Am J Kidney Dis. 2005;46:1099–106.
Chua M, et al. Traditional uses and potential health benefits of Amorphophallus konjac K. Koch ex N.E.Br. J Ethnopharmacol. 2010;128:268–78.
Cicero AFG, Ertek S. Metabolic and cardiovascular effects of berberine: from preclinical evidences to clinical trial results. Clin Lipidol. 2009;4(5):553–63.
Cicero AFG, et al. Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: a pilot study. Complement Ther Med. 2005;13:273–8.
Cicero AFG, et al. Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents in humans. Arzneimittelforschung. 2007;57:26–30.
Cicero AFG, et al. Long-term efficacy and tolerability of a largely marketed multicomponent nutraceutical in overweight and normoweight dyslipidaemic patients. Nutrafoods. 2012;11(2):15–21.
Cicero AFG, et al. Tolerability and safety of commonly used dietary supplements and nutraceuticals with lipid-lowering effects. Expert Opin Drug Saf. 2012;11(5):753–66. doi:10.1517/14740338.2012.705827.
Cicero AFG, et al. Effect of a lipid-lowering nutraceutical on pulse-wave-velocity in hypercholesterolemic patients with or without chronic kidney disease. Open Hypertens J. 2013;5:18–22.
Cicero AFG, et al. Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects. Nutr Res. 2013;33(8):622–8. doi:10.1016/j.nutres.2013.05.01.
Cicero AFG, et al. Nutraceuticals for metabolic syndrome management: from laboratory to benchside. Curr Vasc Pharmacol. 2014;12(4):565–71.
Cicero AFG, et al. Berberine and monacolin effects on the cardiovascular risk profile of women with oestroprogestin-induced hypercholesterolemia. High Blood Press Cardiovasc Prev. 2014;21(3):221–6. doi:10.1007/s40292-014-0052-5.
Deng R. Therapeutic effects of guggul and its constituent guggulsterone: cardiovascular benefits. Cardiovasc Drug Rev. 2007;25(4):375–90.
Derosa G, et al. Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther. 2012;12(8):1113–24.
Eisenbrand G. Toxicological evaluation of red mould rice. Mol Nutr Food Res. 2006;50:322–7.
El Khoury D, Anderson GH. Recent advances in dietary proteins and lipid metabolism. Curr Opin Lipidol. 2013;24(3):207–13. doi:10.1097/MOL.0b013e3283613bb7.
Gheit O, et al. Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidemia. Eur J Intern Med. 2009;20:e57–61.
Gliozzi M, et al. Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia. Int J Cardiol. 2013;170(2):140–5. doi:10.1016/j.ijcard.2013.08.125.
Grieco A, et al. A cute hepatitis caused by a natural lipid-lowering product: when “alternative” medicine is no “alternative” at all. J Hepatol. 2009;50:1273–7.
Grill JP, et al. Effects of Lactobacillus amylovorus and Bifidobacterium breve on cholesterol. Lett Appl Microbiol. 2000;31:154–6.
Grundy SM. Stanol esters as a component of maximal dietary therapy in the National Cholesterol Education Program Adult Treatment Panel III report. Am J Cardiol. 2005;96(suppl):47D–50.
Guardamagna O, et al. Primary hyperlipidemias in children: effect of plant sterol supplementation on plasma lipids and markers of cholesterol synthesis and absorption. Acta Diabetol. 2011;48:127–33.
Guo Z, et al. Influence of consumption of probiotics on the plasma lipid profile: a meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2011;21:844–50.
Gylling H, et al. The effect of a very high daily plant stanol ester intake on serum lipids, carotenoids, and fat soluble vitamins. Clin Nutr. 2010;29:112–8.
Gylling H, et al. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis. 2014;232(2):346–60. doi:10.1016/j.atherosclerosis.2013.11.043.
Halbert SC, et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol. 2010;105(2):198–204.
Harland JI, Haffner TA. Systematic review, meta-analysis and regression of randomized controlled trials reporting an association between an intake of circa 25 g soya protein per day and blood cholesterol. Atherosclerosis. 2008;200:13–27.
Hutchins AM, et al. Hypertensive crisis associated with high dose soy isoflovane supplementation in a post-menopausal woman; a case report. BMC Womens Health. 2005;5:9.
Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs. A systematic review. Drugs. 2001;61:2163–75.
Kang Q, Chen A. Curcumin suppresses expression of low-density lipoprotein receptor, leading to the inhibition of LDL-induced activation of hepatic stellate cells. Br J Pharmacol. 2009;157:1354–67.
Keithley J, Swanson B. Glucomannan and obesity: a critical review. Altern Ther Health Med. 2005;11:30–4.
Keithley J, et al. A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia. Nutrition. 2002;18:201–4.
Klaver FA, Van der Meer V. The assumed assimilation of cholesterol by Lactobacilli and Bifidobacterium bifidum is due to their bile salt –deconjugating activity. Appl Environ Microbiol. 1993;59:1120–4.
Kim A, et al. Green tea catechins decrease total and low-density lipoprotein cholesterol: a systematic review and meta-analysis. J Am Diet Assoc. 2011;111:1720–9.
Kong W, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10:1344–51.
Kumar M, et al. Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res. 2012;2012:902917.
Kwak JS, et al. Garlic powder intake and cardiovascular risk factors: a meta-analysis of randomized controlled clinical trials. Nutr Res Pract. 2014;8(6):644–54. doi:10.4162/nrp.2014.8.6.644.
Lenz TL. Therapeutic lifestyle changes and pharmaceutical care in the treatment of dyslipidemias in adults. J Am Pharm Assoc. 2005;45(4):492–9.
Li G, et al. A tea catechin, epigallocatechin-3-gallate, is a unique modulator of the farnesoid X receptor. Toxicol Appl Pharmacol. 2012;258(2):268–74.
Lin YL, et al. Biologically active components and nutraceuticals in Monascus-fermented rice: a review. Appl Microbiol Biotechnol. 2008;77:965–73.
Liu J, et al. Chinese red yeast rice (monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med. 2006;1:4.
Liu ZL, et al. Chinese herbal medicines for hypercholesterolemia. Cochrane Database Syst Rev. 2011;(7):CD008305.
Macan H, et al. Aged garlic extract may be safe for patients on warfarin therapy. J Nutr. 2006;136(3 Suppl):793S–5.
Maciejko JJ, et al. Psyllium for the reduction of cholestyramine-associated gastrointestinal symptoms in the treatment of primary hypercholesterolemia. Arch Fam Med. 1994;3:955–60.
Mannarino MR, et al. Nutraceuticals for the treatment of hypercholesterolemia. Eur J Intern Med. 2014;25(7):592–9. doi:10.1016/j.ejim.2014.06.008.
Marinangeli CP, et al. Policosanols as nutraceuticals: fact or fiction. Crit Rev Food Sci Nutr. 2010;50:259–67.
Martino F, et al. Effect of dietary supplementation with glucomannan on plasma total cholesterol and low density lipoprotein cholesterol in hypercholesterolemic children. Nutr Metab Cardiovasc Dis. 2005;15:174–80.
McCarty MF. Glucomannan minimizes the postprandial insulin surge: a potential adjuvant for hepatothermic therapy. Med Hypotheses. 2002;58(6):487–90.
McGowan MP, Proulx S. Nutritional supplements and serum lipids: does anything work? Curr Atheroscler Rep. 2009;11:470–6.
Mechanick JI, et al. AACE Nutrition Guidelines Taskforce. American Association of Clinical Endocrinologists medical guidelines for the clinical use of dietary supplements and nutraceuticals. Endocr Pract. 2003;9:417–70.
Mensink RP, et al. Plant stenols dose dependently decrease LDL cholesterol concentrations but not cholesterol standardized fat soluble antioxidant concentrations, at intakes up to 9g/d. Am J Clin Nutr. 2010;92:24–33.
Mogadishian MH, et al. Proatherogenic and antiatherogenic effects of probucol and phytosterols in apolipoprotein E-deficient mice: possible mechanisms of action. Circulation. 1999;99:1733–9.
Mollace V, et al. Hypolipemic and hypoglycaemic activity of bergamotpolyphenols: from animal models to human studies. Fitoterapia. 2011;82(3):309–16. doi:10.1016/j.fitote.2010.10.014.
Moreyra AE, et al. Effect of combining psyllium fiber with simvastatin in lowering cholesterol. Arch Intern Med. 2005;165:1161–6.
Morgan LM, et al. The effect of soluble- and insoluble-fibre supplementation on post-prandial glucose tolerance, insulin and gastric inhibitory polypeptide secretion in healthy subjects. Br J Nutr. 1990;64:103–10.
Moruisi KG, et al. Phytosterols/stanols lower cholesterol concentrations in familial hypercholesterolemic subjects: a systematic review with meta-analysis. J Am Coll Nutr. 2006;25:41–8.
Mullen E, et al. Soy isoflavones affect sterol regulatory element binding proteins (SREBPs) and SREBP-regulated genes in HepG2 cells. J Nutr. 2004;134:2942–7.
Nijjar PS, et al. Role of dietary supplements in lowering low-density lipoprotein cholesterol: a review. J Clin Lipidol. 2010;4(4):248–58.
Potter SM. Overview of proposed mechanisms for the hypocholesterolemic effect of soy. J Nutr. 1995;125(3 Suppl):606S–11.
Ras RT, et al. LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges: a meta-analysis of randomised controlled studies. Br J Nutr. 2014;112(2):214–9. doi:10.1017/S0007114514000750.
Ried K, et al. Effect of garlic on serum lipids: an updated meta-analysis. Nutr Rev. 2013;71(5):282–99. doi:10.1111/nure.12012.
Samman S, et al. Green tea or rosemary extract added to foods reduces nonheme-iron absorption. Am J Clin Nutr. 2001;73:607–12.
Scholle JM, et al. The effect of adding plant sterols or stanols to statin therapy in hypercholesterolemic patients: systematic review and meta-analysis. J Am Coll Nutr. 2009;28:517–24.
Shirashi M, et al. Association between serum folate levels and tea consumption during pregnancy. Biosci Trends. 2010;4:225–30.
Shrestha S, et al. A combination of psyllium and plant sterols alters lipoprotein metabolism in hypercholesterolemic subjects by modifying the intravascular processing of lipoproteins and increasing LDL uptake. J Nutr. 2007;137:1165–70.
Singh DK, et al. Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase. J Pharmacol Exp Ther. 2006;318:1020–6.
Sirtori CR, Lovati MR. Soy proteins and cardiovascular disease. Curr Atheroscler Rep. 2001;3:47–53.
Sood N, et al. Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. Am J Clin Nutr. 2008; 88(4):1167–75.
Stock J. Focus on lifestyle: EAS Consensus Panel Position Statement on Phytosterol-added Foods. Atherosclerosis. 2014;234(1):142–5. doi:10.1016/j.atherosclerosis.2014.01.047.
Tokunaga S, et al. Green tea consumption and serum lipids and lipoproteins in a population of healthy workers in Japan. Ann Epidemiol. 2002;12:157–65.
Torres N, et al. Regulation of lipid metabolism by soyprotein and its implication in diseases mediated by lipid disorders. J Nutr Biochem. 2006;17:365–73.
Trimarco B, et al. Clinical evidence of efficacy of red yeast rice and berberine in a large controlled study versus diet. Med J Nutrition Metab. 2011;4:133–40.
Vega-López S, et al. Sex and hormonal status modulate the effects of psyllium on plasma lipids and monocyte gene expression in humans. J Nutr. 2003;133:67–70.
Vergara-Jimenez M, et al. Hypolipidemic mechanisms of pectin and pysllium in guinea pigs fed high fat-sucrose diets: alterations on hepatic cholesterol metabolism. J Lipid Res. 1998;39:1455–65.
Vrzal R, et al. Activation of the arylhydrocarbon receptor by berberine in HepG2 and H4IIEcells: Biphasic effect on CYP1A1. Biochem Pharmacol. 2005;70:925–36.
Vuksan V, et al. Konjac-Mannan and American ginsing: emerging alternative therapies for type 2 diabetes mellitus. J Am Coll Nutr. 2001;20(S5):370S–80.
Weghuber D, Widhalm K. Effect of 3 month treatment of children and adolescents with familial and polygenic hypercholesterolemia with a soy-substituted diet. Br J Nutr. 2008;99:281–6.
Wei ZH, et al. Time- and dose-dependent effect of psylium on serum lipids in mild- to- moderate hypercholesterolemia: a meta—analysis of controlled trials. Eur J Clin Nutr. 2009;63:821–7.
Weingärtner O, et al. Vascular effects of diet supplementation with plant sterols. J Am Coll Cardiol. 2008;51(16):1553–61.
Weingärtner O, et al. Controversial role of plant sterol esters in the management of hypercholesterolaemia. Eur Heart J. 2009;30(4):404–9.
Weingärtner O, et al. Differential effects on inhibition of cholesterol absorption by plant stanol and plant sterol esters in apoE−/− mice. Cardiovasc Res. 2011;90(3):484–92.
Xin HW, et al. The effects of berberine on the pharmacokinetics of cyclosporine A in healthy volunteers. Methods Find Exp Clin Pharmacol. 2006;28:25–9.
Yin J, et al. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57:712–7.
Yu L. The structure and function of Niemann-Pick C1-like 1 protein. Curr Opin Lipidol. 2008;19(3):263–9.
Zheng XX, et al. Green tea intake lowers fasting serum total and LDL cholesterol in adults: a meta-analysis of 14 randomized controlled trials. Am J Clin Nutr. 2011;94:601–10.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Cicero, A.F.G., Colletti, A. (2015). Statins and Nutraceuticals/Functional Food: Could They Be Combined?. In: Banach, M. (eds) Combination Therapy In Dyslipidemia. Adis, Cham. https://doi.org/10.1007/978-3-319-20433-8_11
Download citation
DOI: https://doi.org/10.1007/978-3-319-20433-8_11
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-20432-1
Online ISBN: 978-3-319-20433-8
eBook Packages: MedicineMedicine (R0)